Clinical Trials Logo

Clinical Trial Summary

While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases. Never smokers with lung cancer typically present with different molecular profiles from that of smokers, which results in prognostic and therapeutic implications. Molecular changes in NSCLC that have therapeutic significance include mutations in the epidermal growth factor receptor (EGFR) and rearrangements in the anaplastic lymphoma kinase (ALK) gene. These driver mutations typically are present in lung tumors found in never or light smokers. The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone, 12.3 vs. 10.3 months respectively. Results from the POINTBREAK trial demonstrated that carboplatin + pemetrexed + bevacizumab is an alternative option to carboplatin + paclitaxel + bevacizumab, with comparable survival but less toxicity. In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. The PD-1 inhibitor nivolumab and the PD-L1 inhibitor atezolizumab have shown prolonged survival in comparison to docetaxel in patients who previously progressed with chemotherapy, irrespective of PD-L1 expression. Thus, this study combines immunotherapeutic agent atezolozumab with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin and pemetrexed).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03786692
Study type Interventional
Source Fox Chase Cancer Center
Contact Joseph Treat, MD
Phone 215-214-4297
Email Joseph.Treat2@fccc.edu
Status Recruiting
Phase Phase 2
Start date September 4, 2019
Completion date January 2027

See also
  Status Clinical Trial Phase
Completed NCT04776083 - Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients Phase 3
Active, not recruiting NCT03288870 - Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) Phase 2/Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03042221 - Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Recruiting NCT05372081 - Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
Recruiting NCT03774732 - PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Phase 3
Completed NCT03406468 - Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer Phase 2
Recruiting NCT04856176 - A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy Phase 2
Terminated NCT02967133 - A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Phase 2
Completed NCT04710459 - Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC N/A
Recruiting NCT03605602 - A Real World Study Based on NGS (TRUMPRWS)